Abstract
Recently, post-transplant cyclophosphamide (PTCy) -based HLA-haploidentical stem cell transplantation (PTCy-haploSCT) has been increasingly performed. The mechanism of GVHD prevention by PTCy is selective depletion of proliferating alloreactive T cells, while preserving non-alloreactive T cells. Several studies have reported that the incidence of non-relapse mortality, relapse, disease-free survival, and overall survival after PTCy-haploSCT are equivalent to those after HLA-matched SCT. Furthermore, the incidence of GVHD, especially chronic GVHD, after PTCy-haploSCT was lower than that of HLA-matched SCT. In Japan, we have conducted several prospective, multicenter, phase II studies since 2013. To reduce relapse, several strategies have been developed. In the first study (Haplo13), we used peripheral blood stem cells and added busulfan (BU) to the original non-myeloablative regimen developed by a Johns Hopkins group. In the second study, we used a BU- or TBI-based myeloablative conditioning regimen (Haplo14 MAC). In the third study, we reduced the dose of PTCy (Haplo16 RIC). In the latest study (Haplo17), we reduced the dose and/or duration of MMF and tacrolimus. We hope that these studies improve the outcome of PTCy-haploSCT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.